XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.23.3

Grant Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Jan. 13, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Reserve for remaining estimated manufacturing expenses |  | $ 146,111 |  | $ 146,111 |  | $ 146,111 |  | $ 489,090
Other current assets |  | 4,800 |  | 4,800 |  | 4,800 |  |
VIR Biomedical Advanced Research and Development Authority | Grant revenue |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenue from grants |  |  |  | 2,900 |  | 29,000 |  |
Human Immunodeficiency Virus ('HIV') Grant | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Grant awarded amount. maximum |  | 49,900 |  | 49,900 |  | 49,900 |  |
Vaccinal Antibody Grant | Grant revenue |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenue from grants |  |  |  | 3,800 | $ 2,800 | 10,500 | $ 7,400 |
Vaccinal Antibody Grant | Bill And Melinda Gates Foundation |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Common stock shares purchased (in shares) | 881,365 |  |  |  |  |  |  |
Common stock, shares purchased price (in USD per share) | $ 45.38 |  |  |  |  |  |  |
Common stock, shares purchased, aggregate purchase price | $ 40,000 |  |  |  |  |  |  |
Common stock, shares issued, fair market value | $ 28,500 |  |  |  |  |  |  |
Closing stock price (in USD per share) | $ 37.65 |  |  |  |  |  |  |
Premium received | $ 11,300 |  |  |  |  |  |  |
Deferred revenue |  | 15,300 |  | 15,300 |  | 15,300 |  | 15,500
Reserve for remaining estimated manufacturing expenses |  | 9,200 |  | 9,200 |  | 9,200 |  | $ 7,700
BARDA |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Base period funding |  |  | $ 55,000 |  |  |  |  |
New funding |  | 50,100 |  | 50,100 |  | 50,100 |  |
Potential future reimbursement |  | 60,900 |  | 60,900 |  | 60,900 |  |
Total Awarded Amount |  |  |  |  |  | 116,300 |  |
BARDA | development of VIR-7229 through a Phase 1 clinical trial |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
New funding |  | 40,000 |  | 40,000 |  | 40,000 |  |
BARDA | New Monoclonal Antibody Discovery |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
New funding |  | 10,100 |  | $ 10,100 |  | $ 10,100 |  |
BARDA | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Maximum grant amount to be received |  |  | $ 1,000,000 |  |  |  |  |
Additional funding |  | $ 11,200 |  |  |  |  |  |

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479432/944-30-50-2B Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2 + Details
Name: | us-gaap_DeferredIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of current assets classified as other. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of revenue that is not accounted for under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RevenueNotFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Additional Funding for Grant Base Period + References No definition available. + Details
Name: | vir_AdditionalFundingForGrantBasePeriod
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of funding during the base period + References No definition available. + Details
Name: | vir_AmountOfFundingBasePeriod
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Closing stock price + References No definition available. + Details
Name: | vir_ClosingStockPrice
Namespace Prefix: | vir_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights and Obligations, Funding + References No definition available. + Details
Name: | vir_CollaborativeArrangementRightsAndObligationsFunding
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Common stock, shares issued, fair market value + References No definition available. + Details
Name: | vir_CommonStockSharesIssuedFairMarketValue
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Common Stock, Shares Purchased + References No definition available. + Details
Name: | vir_CommonStockSharesPurchased
Namespace Prefix: | vir_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common Stock, Shares Purchased , Aggregate Purchase Price + References No definition available. + Details
Name: | vir_CommonStockSharesPurchasedAggregatePurchasePrice
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Common Stock, Shares Purchased, Share Price + References No definition available. + Details
Name: | vir_CommonStockSharesPurchasedSharePrice
Namespace Prefix: | vir_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Grant Amount To Be Received + References No definition available. + Details
Name: | vir_GrantAmountToBeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum grant awarded amount. + References No definition available. + Details
Name: | vir_GrantAwardedAmount
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential Future Reimbursement + References No definition available. + Details
Name: | vir_PotentialFutureReimbursement
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total Awarded Amount + References No definition available. + Details
Name: | vir_TotalAwardedAmount
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Underlying shares, Premium received + References No definition available. + Details
Name: | vir_UnderlyingSharesPremiumReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=vir_VirBiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_DevelopmentOfVIR7229ThroughPhase1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_NewMonoclonalAntibodyDiscoveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |